Quest Diagnostics: Strong Performance and Promising Outlook Justify Buy Rating
I'm PortAI, I can summarize articles.
Andrew Brackmann has issued a Buy rating for Quest Diagnostics, citing strong third-quarter results that exceeded expectations. Key drivers include increased utilization, stable pricing, and successful mergers. The company reported impressive organic revenue growth and raised its full-year guidance, reinforcing its financial health. Mizuho Securities also maintains a Buy rating with a $210 price target. These factors support the premium valuation of Quest Diagnostics' shares.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments